Indeed in an elegant study published while this manuscript was under review, Merino et al.23 demonstrated the potential of MCL-1 inhibition in combination with conventional chemotherapies for increased efficacy in PDX models of TN and HER2-amplified breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.